Navigation Links
Hospira Reports Third-Quarter 2009 Results
Date:10/27/2009

eptember 30, 2008 Reconciliation of GAAP to Non-GAAP Financial Measures: ----------------------------------------------------------------------- Income Gross From Net Diluted Profit (1) Operations Income EPS --------- ---------- ------ ------- GAAP financial measures $986.0 $362.1 $216.3 $1.34 Specified items: Facilities Optimization charges (A) 11.5 25.9 16.0 0.10 Amortization of Mayne Pharma intangible assets (B) 46.8 46.8 31.4 0.20 Integration-related charges (C) 5.8 23.6 17.6 0.11 Acquired in-process research and development - 0.5 0.5 - --------- ---------- ------ ------- Adjusted financial measures $1,050.1 $458.9 $281.8 $1.75 ========= ========== ====== ======= GAAP results for the nine months ended September 30, 2008 include: A -- Facilities Optimization charges: $11.5 million reported in Cost of products sold, $13.8 million reported in Restructuring and impairment and $0.6 million reported in Research and development. These charges relate to facilities optimization from the closure or departure from certain manufacturing and R&D facilities and include costs for severance and other employee benefits, accelerated depreciation and relocation of production and R&D operations. B -- Amortization of Mayne Pharma intangible assets is reported in Cost of products sold. C -- Integration-related charges: $5.8 million reported in Cost of product
'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... (OTC Bulletin Board: AEMD ), the pioneer ... and cancer, today announced that it has entered into ... the opportunity for Aethlon to commercialize its Hemopurifier® treatment ... India.  The therapeutic focus at each center will be ...
... 18, 2010 ... if (typeof(lpUnit)==,undefined,) var ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s ... one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) ...
Cached Medicine Technology:Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 2Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 3Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 4Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 5New Report - Telemedicine Market in Brazil, Russia, India, China (BRIC) - Advanced Technologies, Global Forecast by MarketsandMarkets 2New Report - Telemedicine Market in Brazil, Russia, India, China (BRIC) - Advanced Technologies, Global Forecast by MarketsandMarkets 3New Report - Telemedicine Market in Brazil, Russia, India, China (BRIC) - Advanced Technologies, Global Forecast by MarketsandMarkets 4New Report - Telemedicine Market in Brazil, Russia, India, China (BRIC) - Advanced Technologies, Global Forecast by MarketsandMarkets 5New Report - Telemedicine Market in Brazil, Russia, India, China (BRIC) - Advanced Technologies, Global Forecast by MarketsandMarkets 6New Report - Telemedicine Market in Brazil, Russia, India, China (BRIC) - Advanced Technologies, Global Forecast by MarketsandMarkets 7New Report - Telemedicine Market in Brazil, Russia, India, China (BRIC) - Advanced Technologies, Global Forecast by MarketsandMarkets 8
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... solution, WELLINGTON, Fla., Feb. 26 ... (http://www.QuantumMD.com ) today announced a,multi-dimensional, six ... Medical Technologies, Inc. with Texas-based Net.Orange,Inc., inventor ... and,many general and therapeutic-specific technology solutions., ...
... American Heart Association says high blood sugar condition linked ... News) -- A national effort is needed to deal ... patients, says an American Heart Association scientific statement released ... questions about the condition, also known as hyperglycemia, in ...
... - IVIS Imaging Systems ... Caliper Life,Sciences, Inc. (Nasdaq: CALP ), a leading ... research, today reported its fourth,quarter and full year financial results ... 16% from $34.7 million in the same,period in 2006. Net ...
... complementary businesses - Transaction ... - $12-14 million of expected annual synergies ... per share in 2009, LISLE, IL, and PORT WASHINGTON, ... the "Company") (NASDAQ: SXCI, TSX:,SXC) and National Medical Health Card ...
... TORONTO, Feb. 26 /PRNewswire-FirstCall/ - ... to the development and,commercialization of cancer ... data,on the Company,s Neuradiab product candidate ... multiforme (GBM) were published in the ...
... HOUSTON, Feb. 26 Carriage Services, Inc.,(NYSE: CSV ) ... on Thursday, March 6, 2008 after the market closes. In,conjunction ... will be broadcast live over the Internet, for Friday, March ... Carriage Services Fourth Quarter 2007 Earnings Conference Call, When: ...
Cached Medicine News:Health News:The Quantum Group Announces Strategic Technology Alliance 2Health News:The Quantum Group Announces Strategic Technology Alliance 3Health News:The Quantum Group Announces Strategic Technology Alliance 4Health News:National Effort Needed to Address Hyperglycemia in Heart Patients 2Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 2Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 3Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 4Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 5Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 6Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 7Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 8Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 9Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 10Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 11Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 12Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 13Health News:Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results 14Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 2Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 3Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 4Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 5Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 6Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 7Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 8Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 3Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 4Health News:Carriage Services Announces Fourth Quarter and Year-End Earnings Release and Conference Call Schedule 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: